176 related articles for article (PubMed ID: 16911499)
21. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient.
Kaplan B; West P; Neeley H; Martellotto J; Iqbal R; Gangemi A; Hatipoglu B; Benedetti E; Oberholzer J
Clin Transplant; 2008; 22(2):250-3. PubMed ID: 18339148
[TBL] [Abstract][Full Text] [Related]
22. Initial single-center experience with sirolimus after lung transplantation.
Lischke R; Simonek J; Matousovic K; Stolz AJ; Schützner J; Vojácek J; Burkert J; Davidová R; Pafko P
Transplant Proc; 2006 Nov; 38(9):3006-11. PubMed ID: 17112886
[TBL] [Abstract][Full Text] [Related]
23. Late-onset tacrolimus-associated cerebellar atrophia in a heart transplant recipient.
Kaczmarek I; Schmauss D; Sodian R; Beiras-Fernandez A; Oberhoffer M; Daebritz S; Schoenberg SO; Reichart B
J Heart Lung Transplant; 2007 Jan; 26(1):89-92. PubMed ID: 17234523
[TBL] [Abstract][Full Text] [Related]
24. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Pea F; Tavio M; Pavan F; Londero A; Bresadola V; Adani GL; Furlanut M; Viale P
Antivir Ther; 2008; 13(5):739-42. PubMed ID: 18771060
[TBL] [Abstract][Full Text] [Related]
25. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution.
Toth CC; Burak K; Becker W
Headache; 2005 Mar; 45(3):245-6. PubMed ID: 15836601
[TBL] [Abstract][Full Text] [Related]
26. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
27. [Amiodarone--still a useful antiarrhythmic drug].
Gjesdal K
Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1532-3. PubMed ID: 18587462
[TBL] [Abstract][Full Text] [Related]
28. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
[TBL] [Abstract][Full Text] [Related]
29. Amiodarone-cyclosporine interaction in a heart transplant patient.
Nicolau DP; Uber WE; Crumbley AJ; Strange C
J Heart Lung Transplant; 1992; 11(3 Pt 1):564-8. PubMed ID: 1610865
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
31. Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration.
DeVore KJ; Hobbs RA
Pharmacotherapy; 2007 Mar; 27(3):472-5. PubMed ID: 17316159
[TBL] [Abstract][Full Text] [Related]
32. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant.
Teachey DT; Jubelirer T; Baluarte HJ; Wade A; Manno CS
Pediatr Blood Cancer; 2009 Dec; 53(6):1114-6. PubMed ID: 19621445
[TBL] [Abstract][Full Text] [Related]
33. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.
Surowiec D; DePestel DD; Carver PL
Pharmacotherapy; 2008 Jun; 28(6):719-29. PubMed ID: 18503400
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
35. Preapheresis immunosuppressive induction: necessary or harmful?
Wennberg L; Genberg H; Tydén G
Transplantation; 2007 Dec; 84(12 Suppl):S37-9. PubMed ID: 18162987
[TBL] [Abstract][Full Text] [Related]
36. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
[TBL] [Abstract][Full Text] [Related]
38. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
40. [Metabolic modifications related to immunosuppressive drugs].
Ducobu J
Rev Med Brux; 2002 Jun; 23(3):156-9. PubMed ID: 12143154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
